Feature | September 04, 2014

Henry Ford Hospital Replaces Heart Valve Outside the Heart

heart valve, heart surgery

A doctor implants a heart valve in Seattle.

September 4, 2014 – For the first time in the United States, doctors at Henry Ford Hospital used a minimally invasive procedure to replace a failing, hard-to-reach heart valve with a new one – and placed it just outside the heart. 

Due to prior medical procedures, the metro Detroit woman was not a candidate for traditional open-heart surgery to replace her failing tricuspid valve. One major U.S. medical center turned her down for treatment. Doctors at another said her only option was a heart transplant. Henry Ford is the first hospital in the U.S. to perform the unique, transcatheter tricuspid valve replacement, which was pioneered in Germany. The woman’s tricuspid valve, one of four valves that regulates blood flow in the heart, was replaced during the 2-hour procedure July 31. The woman stayed five days in Henry Ford Hospital and was released to her home. 

“There are a lot of people who have damage of the tricuspid valve, and the surgery is risky, so doctors just try to give them medical therapy,” says William O’Neill, M.D., medical director of Henry Ford’s Center for Structural Heart Disease and lead physician for the procedure. “They get a lot of swelling and severe liver congestion. They’re in and out of the hospital, and it really causes a lot of morbitity. So there’s a huge, unmet clinical need. Individuals with this type of valve problem now have another option.”
 
Approximately 5 million people in the U.S. are diagnosed with heart valve disease annually. With an aging population that is often too frail for open-heart surgery, more than 20,000 Americans die of the disease each year, according to the American Heart Association. More than 9,100 heart patients undergo tricuspid valve surgery in the United States annually, according to the Society of Thoracic Surgeons. Replacing a tricuspid valve is one of the more difficult heart surgeries due to the valve’s location, typically requiring open heart surgery, O’Neill explains. The tricuspid valve is in the middle of the heart, in between the right ventricle and the right atrium. 
 
In the unique procedure at Henry Ford Hospital, O’Neill threaded a catheter through in a vein in the patient’s groin to her upper abdomen. There, he inserted the TAVR valve at the junction of the right atrium and the inferior vena cava (IVC), the main vein that brings deoxygenated blood back into the heart. 
 
The Henry Ford team first braced the inside of the IVC with a metal, expandable stent. He then used the catheter to insert and expand a TAVR valve to fit snugly inside. The team used 3-D modeling to create a working replica of the patient’s heart, which helped them properly plan the procedure and choose an appropriately sized valve in advance. 
 
Once deployed, the new valve stopped blood from leaking and pooling in the patient’s abdomen and lower extremities. “There’s already a huge drop in the pressure in the abdomen,” O’Neill says. Doctors monitored pressure through catheters inserted in the IVC above and below the new valve. 
 
O’Neill was assisted by Adam Greenbaum, M.D., director of the Cardiac Catheterization Lab at Henry Ford Hospital, and visiting cardiologist Brian O’Neill, M.D., assistant professor of medicine at the Temple Heart and Vascular Center. 
 
For more information: http://www.henryford.com/

Related Content

Boston Scientific Receives FDA Approval for Lotus Edge Aortic Valve System
Feature | Heart Valve Technology | April 23, 2019 | Dave Fornell, Editor
Boston Scientific Corp. announced it has received U.S. Food and Drug Administration (FDA) approval for the Lotus Edge...
New Consensus Document Explores Optimized Care for Valvular Heart Disease Patients
News | Heart Valve Technology | April 22, 2019
April 22, 2019 — Five cardiovascular professional societies released a new consensus document on optimizing care for
Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor
Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a transcatheter aortic valve valve...
 Evolut Low Risk Trial compared the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. The randomized trial, which met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3 vs. 6.7 percent; posterior probability of non-inferiority >0.999), was presented at the American College of Cardiology (ACC) 2019 meeting
News | Heart Valve Technology | April 03, 2019
April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut transc
TAVR Outperforms Surgery in Younger, Low-Risk Aortic Stenosis Patients
News | Heart Valve Technology | March 22, 2019
Among patients with severe symptomatic aortic stenosis at low surgical risk, transcatheter aortic valve replacement (...
ACC Launches Transcatheter Valve Certification
News | Heart Valve Technology | March 14, 2019
March 14, 2019 — Beginning in mid-2019, hospitals performing...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S.
Overlay Init